This inventor holds 1 USPTO granted patent. Top assignee: Amgen Canada Inc.. Active years: 1999.
Company Filing History:
Years Active: 1999
Title: Armin Reitmair: Innovator in Genetic Research
Introduction
Armin Reitmair is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of genetic research, particularly in the study of non-human mammals and their genetic modifications. His work has implications for understanding various diseases, including cancer.
Latest Patents
Armin Reitmair holds a patent titled "MSH2 disrupted mice develop lymphomas." This patent discloses non-human mammals that possess a disrupted MSH2 gene. Specifically, it details animals with a disruption in one or both alleles of the MSH2 gene or its homolog. The patent highlights that animals homozygous for this disruption are viable beyond the embryonic stage but exhibit an increased incidence of lymphoma, intestinal adenomas, carcinomas, and squamous cell tumors of the skin. Notably, the patent describes mice whose genome includes a disrupted MSH2 gene, leading to a higher occurrence of spontaneous lymphoma compared to wild-type mice. He has 1 patent to his name.
Career Highlights
Armin Reitmair has had a distinguished career in genetic research. His work at Amgen Canada Inc. has allowed him to explore innovative approaches to genetic modifications and their effects on health. His research has contributed to a deeper understanding of genetic disorders and potential therapeutic avenues.
Collaborations
Armin has collaborated with several prominent researchers in his field, including Tak Wah Mak. These collaborations have enhanced the scope and impact of his research, leading to advancements in genetic studies.
Conclusion
Armin Reitmair's contributions to genetic research, particularly through his patent on MSH2 disrupted mice, underscore his role as an innovator in the field. His work continues to influence the understanding of genetic diseases and potential treatments.